AbstractThere were examined 65 children with partially controlled and uncontrolled bronchial asthma (BA) in the exacerbation phase at the age of 5-7 years. Acute respiratory viral infections were often complicated by wheezing (49.2%) and pneumonia (16.8%). Unfortunately, most of these episodes were treated using antibacterial therapy despite normal values of the complete blood count and no infiltrative changes in the chest radiography. Children of Group I underwent basic therapy of BA in the form of inhaled corticosteroids (ICS), patients of Group II received antileukotriene drug – montelukast (Milukante) in addition to basic therapy of BA. When assessing the values of peakflowmetry a peak flow rate was found to be improved in all children (р<0.001), however, in children who additionally received montelukast better parameters of the average daily bronchial patency (ADBP) were observed 77.29±1.17% vs. 72.87±0.73% in Group І (р<0.05). There was a similar tendency when assessing the increase in the ADBP 19.9±1.1% and 23.35±1.18% in Group І and ІІ, respectively. After inpatient treatment, patients were prescribed monotherapy with ICS (Group I) or montelukast (Group II) for 3 months. In children who received montelukast parameters of the ADBP were found to be higher 81.29±1.17% vs. 89.27±1.11% in Group І (р<0.05) and, accordingly, the assessment of general well-being was higher, too. Such differences between groups are explained by the fact that patients preferred taking montelukast to taking ICS.
Shit SM, Revenko NYu. , Gorelko TG, et al. Antileukotriene drug in treatment of allergic diseases in children. Perinatologiya i pediatriya 2013;3(55):92-95.
Reheda MS, Reheda MM, Furdychko LO, et al. Bronchial asthma [monograph]. Lviv. 2012;147.
Zaitseva OV. Wheezing in paediatric practice. Role of inhaled bronchodilator therapy. Novyny medytsyny ta farmatsii 2008;19(261):43-47.
Korets HYu, Zaliska OM. Pharmacoeconomic aspects of treatment of bronchial asthma on the basis of evidence-based medicine. Provizor 2009;10:45-49.
Korostovtsev DS, Breykin DV. Peak expiration velocity in healthy children. Allergologiya 2006;2:39-42.
Khaitova RM, Ilyina NI, Latysheva TV, et al. Rational pharmacotherapy of allergic diseases. Khaitova RM, Ilyina NI, Latysheva TV,editors. Litterra. Moscow. 2007;502,
Tkach YeP, Khukhlina OS, Voievidka OS et al. Pharmaceutical care. Nova Knyha. Vinnytsia. 2014;519.
Becker LA, Hom J, Villasis-Keever M, et al. Beta2-agonists for acute cough or a clinical diagnosis of acute bronchitis. Cochrane Database Syst Rev. Internet 2015;3(9). Available from: http://www.ncbi.nlm.nih.gov/pubmed/26333656
Global Initiative for Asthma (GINA). Available from: http://www.ginasthma.org/local/uploads/files/GINA_Report2015_Tracked.pdf
Hesselmar B, Enelund A-C, Eriksson B, et al. The heterogeneity of asthma phenotypes in children and young adults. J Allergy. 2012; Article ID 163089, 6-8.
Aganche I, Akdis C, Jutel M, et al. Untangling asthma phenotypes and endotypes. Allergy 2012;67(7):835-846. Available from: http://dx.doi.org/10.1111/j.1398-9995.2012.02832.x PubMed PMID: 22594878. doi: 10.1111/j.1398-9995.2012.02832.x.
Kocevar VS, Bisgaard H, Jönsson L, Valovirta E, Kristensen F, Yin DD, et al. Variations in pediatric asthma hospitalization rates and costs between and within Nordic countries.. Chest 2004;125(5):1680-1684. Available from: http://www.diseaseinfosearch.org/result/633 PubMed PMID: 15136376.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.